AU2016209255B2 - Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases - Google Patents

Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases Download PDF

Info

Publication number
AU2016209255B2
AU2016209255B2 AU2016209255A AU2016209255A AU2016209255B2 AU 2016209255 B2 AU2016209255 B2 AU 2016209255B2 AU 2016209255 A AU2016209255 A AU 2016209255A AU 2016209255 A AU2016209255 A AU 2016209255A AU 2016209255 B2 AU2016209255 B2 AU 2016209255B2
Authority
AU
Australia
Prior art keywords
effective dose
disease
treat
examples
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016209255A
Other languages
English (en)
Other versions
AU2016209255A1 (en
Inventor
Robert Alonso
John Gerard Geisler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitochon Pharmaceuticals Inc
Original Assignee
Mitochon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitochon Pharmaceuticals Inc filed Critical Mitochon Pharmaceuticals Inc
Publication of AU2016209255A1 publication Critical patent/AU2016209255A1/en
Application granted granted Critical
Publication of AU2016209255B2 publication Critical patent/AU2016209255B2/en
Priority to AU2021240120A priority Critical patent/AU2021240120A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2016209255A 2015-01-22 2016-01-21 Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases Active AU2016209255B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021240120A AU2021240120A1 (en) 2015-01-22 2021-09-27 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106365P 2015-01-22 2015-01-22
US62/106,365 2015-01-22
PCT/US2016/014312 WO2016118741A1 (en) 2015-01-22 2016-01-21 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021240120A Division AU2021240120A1 (en) 2015-01-22 2021-09-27 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Publications (2)

Publication Number Publication Date
AU2016209255A1 AU2016209255A1 (en) 2017-08-10
AU2016209255B2 true AU2016209255B2 (en) 2021-07-01

Family

ID=55310938

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016209255A Active AU2016209255B2 (en) 2015-01-22 2016-01-21 Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
AU2021240120A Abandoned AU2021240120A1 (en) 2015-01-22 2021-09-27 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021240120A Abandoned AU2021240120A1 (en) 2015-01-22 2021-09-27 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Country Status (13)

Country Link
US (6) US9763896B2 (enExample)
EP (1) EP3247340B1 (enExample)
JP (3) JP6951976B2 (enExample)
KR (1) KR102690198B1 (enExample)
CN (2) CN116617195A (enExample)
AU (2) AU2016209255B2 (enExample)
BR (1) BR112017015721A2 (enExample)
CA (1) CA2974092A1 (enExample)
ES (1) ES2961334T3 (enExample)
HK (1) HK1247101A1 (enExample)
MX (2) MX392410B (enExample)
PT (1) PT3247340T (enExample)
WO (1) WO2016118741A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016209255B2 (en) 2015-01-22 2021-07-01 Mitochon Pharmaceuticals, Inc. Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives
EP3576739A2 (en) * 2017-01-31 2019-12-11 Paolo L. Manfredi Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10675255B2 (en) 2017-06-23 2020-06-09 Enzo Bochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN116437942A (zh) * 2020-09-29 2023-07-14 Cefo有限公司 包含manf的用于预防或治疗神经精神性疾病的组合物
WO2023205625A2 (en) * 2022-04-18 2023-10-26 Mitochon Pharmaceuticals, Inc. 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases
WO2025051360A1 (en) * 2023-09-06 2025-03-13 Instituto de Medicina Molecular João Lobo Antunes Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
EP2170338A2 (en) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
AU2016209255B2 (en) * 2015-01-22 2021-07-01 Mitochon Pharmaceuticals, Inc. Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2015031756A1 (en) * 2013-08-30 2015-03-05 Yale University Novel 2,4-dinitrophenol formulations and methods using same

Also Published As

Publication number Publication date
US11717497B2 (en) 2023-08-08
JP7440092B2 (ja) 2024-02-28
CN107405315A (zh) 2017-11-28
US10864173B2 (en) 2020-12-15
WO2016118741A1 (en) 2016-07-28
US10220006B2 (en) 2019-03-05
ES2961334T3 (es) 2024-03-11
US20170065536A1 (en) 2017-03-09
US20190142765A1 (en) 2019-05-16
KR102690198B1 (ko) 2024-07-30
US20180125794A1 (en) 2018-05-10
CA2974092A1 (en) 2016-07-28
KR20170104597A (ko) 2017-09-15
EP3247340A1 (en) 2017-11-29
JP6951976B2 (ja) 2021-10-20
AU2016209255A1 (en) 2017-08-10
EP4306167A2 (en) 2024-01-17
MX2022005937A (es) 2022-06-29
US20210052513A1 (en) 2021-02-25
JP2022173519A (ja) 2022-11-18
US20240156750A1 (en) 2024-05-16
MX2017009402A (es) 2017-12-04
MX392410B (es) 2025-03-11
JP2021080286A (ja) 2021-05-27
EP3247340B1 (en) 2023-08-02
EP4306167A3 (en) 2024-03-20
US20160213625A1 (en) 2016-07-28
JP2018502898A (ja) 2018-02-01
HK1247101A1 (zh) 2018-09-21
US9974755B2 (en) 2018-05-22
PT3247340T (pt) 2023-10-31
CN116617195A (zh) 2023-08-22
AU2021240120A1 (en) 2021-10-28
US9763896B2 (en) 2017-09-19
BR112017015721A2 (pt) 2018-04-10

Similar Documents

Publication Publication Date Title
US20240156750A1 (en) Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic Diseases
US20150216850A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US20250188461A1 (en) Methods of treating osmidrosis
WO2020198039A1 (en) Ketamine for treatment of sensory processing deficits
CA2910717C (en) Biotin for use in treating x-linked adrenoleukodystrophy
HK40106997A (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
WO2020247615A1 (en) Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
EP4306167B1 (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
Du et al. The potential of gonadal hormone signalling pathways as therapeutics for dementia
JP7121859B2 (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
Sharma et al. Recovery of the injured neural system through gene delivery to surviving neurons in Parkinson’s disease
KR20220109378A (ko) 병용 요법 방법, 조성물 및 키트
Arenas-Guzmán et al. Onychomycosis
EP2991645B1 (en) Biotin for use in treating x-linked adrenoleukodystrophy
Tankosic Parkinson's disease: new dopaminergic delivery but neuroprotection remains elusive
KAUR et al. A Comparative Trial to Evaluate Amitriptyline and Duloxetine in Painful Diabetic Neuropathy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)